Xitra Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Xitra Therapeutics, founded in 2018 and based in Munich, is a private, pre-clinical stage biotech developing oral small molecule agonists of the Mas and MrgD receptors. The company's platform aims to harness the protective angiotensin-(1-7) pathway for treating severe pediatric and inflammatory conditions, offering a potential advantage over peptide-based therapies. As a subsidiary of Constant Therapeutics, Xitra has secured non-dilutive grant funding and is led by an experienced scientific founder. The company represents a focused effort to address high-unmet-need rare diseases with a novel pharmacological approach.

Rare DiseasesInflammatory DiseasesPediatric Diseases

Technology Platform

Discovery and development of oral, small molecule agonists targeting the Mas and MrgD receptors to mimic the beneficial effects of angiotensin-(1-7) from the Renin Angiotensin System.

Opportunities

The primary opportunity is to establish proof-of-concept for a first-in-class oral Mas/MrgD agonist in high-unmet-need rare pediatric diseases, which offers orphan drug incentives and premium pricing potential.

Success could unlock the platform's application to vast markets in common fibro-inflammatory diseases like pulmonary and renal fibrosis, representing a multi-billion dollar expansion opportunity.

Risk Factors

The core scientific risk is that the novel mechanism of oral Mas/MrgD agonism fails to show efficacy or acceptable safety in human trials.

Financially, the company is reliant on limited grant funding and parent company support, requiring significant future capital for costly clinical development, which may be difficult to secure if early data are weak.

Competitive Landscape

Competition exists from other companies targeting fibrosis and inflammation through various pathways, and potentially from other groups developing angiotensin-(1-7) pathway modulators (e.g., peptide analogs or gene therapies). For its lead rare disease indications, Xitra may compete with gene therapy, cell therapy, and protein replacement strategies, making differentiation on convenience (oral administration) and mechanism critical.

More companies in Small Molecule Drugs →More companies in Germany →